22nd Century Group, Inc., a plant biotechnology company, provides technology that allows to alter the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has 22nd Century Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XXII is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: XXII's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: XXII exceeded the US Tobacco industry which returned -18.4% over the past year.
Return vs Market: XXII exceeded the US Market which returned 19.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is 22nd Century Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs 22nd Century Group (NYSEMKT:XXII) A Risky Investment?
3 months ago | Simply Wall StHow Much Did 22nd Century Group's(NYSEMKT:XXII) Shareholders Earn From Share Price Movements Over The Last Three Years?
5 months ago | Simply Wall StHealth Check: How Prudently Does 22nd Century Group (NYSEMKT:XXII) Use Debt?
Is 22nd Century Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate XXII's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate XXII's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: XXII is unprofitable, so we can't compare its PE Ratio to the XX Tobacco industry average.
PE vs Market: XXII is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XXII's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XXII is overvalued based on its PB Ratio (7.7x) compared to the US Tobacco industry average (4.1x).
How is 22nd Century Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XXII is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XXII is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XXII is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XXII's revenue is expected to decline over the next 3 years (-5.2% per year).
High Growth Revenue: XXII's revenue is forecast to decline over the next 3 years (-5.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XXII's Return on Equity is forecast to be high in 3 years time
How has 22nd Century Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XXII is currently unprofitable.
Growing Profit Margin: XXII is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XXII is unprofitable, and losses have increased over the past 5 years at a rate of 18.8% per year.
Accelerating Growth: Unable to compare XXII's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XXII is unprofitable, making it difficult to compare its past year earnings growth to the Tobacco industry (-4.1%).
Return on Equity
High ROE: XXII has a negative Return on Equity (-38.98%), as it is currently unprofitable.
How is 22nd Century Group's financial position?
Financial Position Analysis
Short Term Liabilities: XXII's short term assets ($33.1M) exceed its short term liabilities ($6.5M).
Long Term Liabilities: XXII's short term assets ($33.1M) exceed its long term liabilities ($819.0K).
Debt to Equity History and Analysis
Debt Level: XXII's debt to equity ratio (3.6%) is considered satisfactory.
Reducing Debt: XXII's debt to equity ratio has reduced from 7.8% to 3.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XXII has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XXII has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 16.2% each year.
What is 22nd Century Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XXII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XXII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XXII's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XXII's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XXII's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Mish (56 yo)
Mr. James E. Mish, also known as Jim, serves as Chief Executive Officer at 22nd Century Group, Inc. since June 22, 2020. He has extensive global executive leadership experience in science-driven organizati...
|President & COO||1.08yrs||US$1.01m||0.056% |
|CFO & Treasurer||7.83yrs||US$484.12k||no data|
|Chief Executive Officer||0.58yr||no data||0.072% |
|VP of Administration & CFO||0.58yr||no data||no data|
|Director of Communications & Investor Relations||0.83yr||no data||no data|
|General Counsel & Corporate Secretary||0.50yr||no data||no data|
|Technical Advisor & Regulatory Affairs Consultant||14yrs||no data||no data|
Experienced Management: XXII's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
|Independent Chairman||1yr||US$201.22k||0.14% |
|Independent Director||7.08yrs||US$201.22k||0.070% |
|Independent Director||1yr||no data||no data|
|Director||0.33yr||no data||no data|
Experienced Board: XXII's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: XXII insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.3%.
22nd Century Group, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: 22nd Century Group, Inc.
- Ticker: XXII
- Exchange: AMEX
- Founded: 1998
- Industry: Tobacco
- Sector: Food, Beverage & Tobacco
- Market Cap: US$386.029m
- Shares outstanding: 138.86m
- Website: https://www.xxiicentury.com
Number of Employees
- 22nd Century Group, Inc.
- 8560 Main Street
- Suite 4
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|XXII||AMEX (NYSE MKT LLC)||Yes||Common Stock||US||USD||Jan 2011|
|22N||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2011|
|0LHJ||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 2011|
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows to alter the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis pl...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/18 00:41|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.